Aragen Life Sciences Announces ₹2,000 Crore Expansion Plan in Hyderabad

Aragen Life Sciences is set to embark on a significant expansion in Hyderabad, earmarking a substantial investment of ₹2,000 crore that will result in the creation of 1,500 new jobs. The expansion will primarily focus on enhancing the capabilities of its facility in Mallapur, Telangana, with a specific emphasis on drug discovery, development, and manufacturing for the global life sciences industry.

The investment announcement was made following a meeting between A Revanth Reddy, the Chief Minister of Telangana, and Manni Kantipudi, the whole-time Director and CEO of Aragen Life Sciences. The meeting took place during the ongoing annual World Economic Forum in Davos.

Expressing his enthusiasm for the investment plans, Chief Minister Reddy remarked, “I am delighted that Aragen Life Sciences, a global leader in pharma, has chosen massive investment plans in Hyderabad. This shows the new government’s resolve to build a next-level vibrant ecosystem, extraordinary infrastructure and showcasing our rich talent pool that can drive innovation to the works.”

Kantipudi, in turn, expressed excitement about the five-year expansion plans, stating, “We are excited about our five-year expansion plans and have decided to invest ₹2,000 crore in Hyderabad, Telangana. Chief Minister Revanth Reddy’s leadership inspires confidence that Hyderabad will consolidate its undisputed national status as headquarters for CROs (contract research organisations) and CDMOs (contract development and manufacturing organisations) over the years.”

Highlighting Hyderabad's appeal, Kantipudi emphasized the city's modern infrastructure, access to top scientific talent in the country, a robust network of suppliers, and an ecosystem conducive to innovation in digital technologies.

Hyderabad, known for its thriving life sciences sector, currently serves more than 1,000 innovators globally in the research and development of new drugs and medical devices. Aragen Life Sciences, with over 20 years of experience, specializes in providing contract research, development, and manufacturing services across the drug development continuum, particularly focusing on the early-stage discovery and development of new molecular entities (NMEs).

HBL